Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Trial Profile

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glycopyrrolate/indacaterol (Primary) ; Indacaterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational
  • Acronyms EXPEDITION; FLIGHT-3
  • Sponsors Novartis
  • Most Recent Events

    • 24 May 2017 Results assessing improvement in lung function with indacaterol/glycopyrrolate twice daily versus indacaterol once daily in patients with moderate-to-severe COPD, presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results from analysis of FLIGHT trials (FLIGHT1, FLIGHT2 and FLIGHT3 studies) presented at the 113th International Conference of the American Thoracic Society
    • 23 May 2017 According to a Sunovion Pharmaceuticals media release, data from this study was presented at the 2017 American Thoracic Society International Conference (ATS 2017).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top